Hartmut Rehwinkel

Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects

Heike Schäcke, Arndt Schottelius, Wolf‐Dietrich Döcke et al. · Proceedings of the National Academy of Sciences · 2003 · 467 citations · Full text

Immunology, Therapeutic Effects, Classical Gcs +17

Identification and Optimization of the First Highly Selective GLUT1 Inhibitor BAY‐876

Hölger Siebeneicher, Arwed Cleve, Hartmut Rehwinkel et al. · ChemMedChem · 2016 · 262 citations · Full text

Pan-mutant IDH1 inhibitor BAY 1436032 for effective treatment of IDH1 mutant astrocytoma in vivo

Stefan Pusch, Sonja Krausert, Viktoria Fischer et al. · Acta Neuropathologica · 2017 · 174 citations

Tumor Biology, Neuro-oncology, Glioma +10

Characterization of ZK 245186, a novel, selective glucocorticoid receptor agonist for the topical treatment of inflammatory skin diseases

Heike Schäcke, TM Zollner, W-D Döcke et al. · British Journal of Pharmacology · 2009 · 122 citations · Full text

Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo

Anuhar Chaturvedi, Lena Herbst, Stefan Pusch et al. · Leukemia · 2017 · 117 citations · Full text

Hematological Malignancy, Medicine, Mixed-phenotype Acute Leukemia +8